Guardian, Oct. 11th 2001, p. 15
Reports the launch of pilot incentive schemes offering team bonuses to frontline NHS staff who meet performance targets.
Health Economics, vol. 10, 2001, p. 479-486
An important political decision has been taken that an increase in major NHS investment will take place, but only if financed by PFI. Problems with PFI schemes arise from:
Guardian, Oct 10th 2001, p. 27
The terms of reference for a Treasury review of NHS funding reveal that the government is committed to maintain access based on clinical need, not ability to pay. The Review team are expected to conclude that spending on the NHS will have to rise faster than economic growth to keep pace with an ageing population and advancing medical techniques.
(See also Independent, Oct. 10th 2001, p. 12; Financial Times, Oct 9th 2001, p.1)
R. Cookson, D. McDaid and A. Maynard
British Medical Journal, vol. 323, Sept. 24th 2001, p. 743-745
NICE considers cost effectiveness but has been reluctant to advise against funding many costly new pharmaceuticals in the NHS in England and Wales. NICE must devise politically acceptable ways of refusing to spend taxpayers' money on costly new drugs and devices that lack demonstrable incremental cost effectiveness. Otherwise, new and often inefficient technologies will continue to fuel the widening gap between public expectations and public willingness to pay for the NHS. NICE should prioritise new national guidance within a fixed growth budget for the net cost of new technologies and in relation to incremental cost effectiveness. If reducing postcode rationing would compromise more important goals of equity or efficiency, NICE should sometimes refuse to issue definite national guidance.